CC-93269 Myeloma Trials

CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.

SparkCures ID	311
Developed By	Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
Generic Name	CC-93269
Treatment Classifications	Bispecific Antibody
Treatment Targets	B-Cell Maturation Antigen (BCMA) CD3

All Clinical Trials

View all active clinical trials around the US.

Verified

View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified

View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified

View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Smoldering Myeloma

No active clinical trials

Monoclonal Gammopathy of Undetermined Significance (MGUS)

No active clinical trials

January 22, 2020

The overall response rate (ORR) in all patients was 43.3% with a stringent complete response/complete response (sCR/CR) of 16.7%
The likelihood of response was dose-dependent. ORR by CC-93269 dose:
- Dose ≤ 3mg (n= 7): 0%
- Dose 3 to 6 mg or fixed-dose 6 mg (n= 14): 7%
- Dose 6 to 10 mg or fixed-dose 10 mg (n= 9): 88.9%
Among the nine patients treated with 10 mg of CC-93269, the ORR was 88.9% with a sCR/CR of 44.4%
The median time to response was 4.1 weeks (range; 4–13.1)
Among 13 responding patients, 11 responses are ongoing
Measurable residual disease (MRD) negativity was achieved by 12 of the 13 responding patients

CC-93269